Matthew Witmer Joins Cartesian Therapeutics as Quality Investigator
Matthew Witmer has joined Cartesian Therapeutics as a Quality Investigator, bringing nearly a decade of GMP experience and a reputation for integrity, collaboration, and technical excellence.
Cartesian Therapeutics, a clinical-stage biotech advancing RNA cell therapies for autoimmune diseases, has welcomed Matthew Witmer to its growing Quality team. With nearly a decade of GMP experience and a strong track record in Quality Investigations, Witmer joins Cartesian as the company advances its lead candidate into Phase III clinical trials.
Born and raised in Frederick, Maryland, Witmer’s career reflects deep local roots and a steady commitment to professional growth. He began his academic journey at Frederick Community College before earning his degree in Environmental Biology from Hood College. His career launched in GMP manufacturing, where he gained hands-on experience across medical devices, human tissues, gene therapy, and aseptic processing. This multidisciplinary foundation would prove vital as he transitioned into Quality and Compliance roles at three CDMOs, including his most recent position at Catalent Pharma Solutions.
At Catalent, Matt Witmer deepened his expertise in Cell and Gene Therapy manufacturing and built a strong reputation as a thoughtful investigator and trusted compliance partner. His ability to navigate complex quality challenges with empathy and clarity set him apart. “Throughout my career, I’ve learned that collaboration and open communication are the keys to building quality-driven solutions,” Witmer shared. “At Cartesian, I’m excited to continue growing while helping ensure the integrity of the products we’re delivering to patients.”
Sneha Saggurthi, Manager of Quality Compliance at Cartesian, reflected on his impact:
“Matt was one of my easiest referrals because I knew he’d be a perfect fit for Cartesian. He’s one of those people with golden retriever energy—easy to connect with, leaves a positive impression, and most importantly, someone you can count on to just get things done... When a role opened up in our quality group at Cartesian, it was a no-brainer. Matt brings that rare mix of technical strength, sound quality-risk mindset, and solid character.”
As Cartesian continues to build out its Quality team in preparation for late-stage development and potential commercialization, Witmer brings not only technical acumen but the kind of integrity and collaborative spirit essential in today’s life sciences landscape.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. A Phase 3 trial of Descartes-08 in patients with generalized myasthenia gravis has received written agreement from the FDA under the Special Protocol Assessment process. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
